NCT01545778: Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR) |
|
|
| Completed | N/A | 646620 | US | Tapentadol IR, Oxycodone IR | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Substance Abuse Detection | 02/12 | 02/12 | | |
NCT01946555: Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain |
|
|
| Completed | N/A | 150 | Europe | Morphine, Fentanyl, Methadone, Buprenorphine, Oxycodone, Hydromorphone, Tapentadol | Mario Negri Institute for Pharmacological Research | Tumor, Cancer Pain, Breakthrough Cancer Pain, Neuropathic Pain | 12/15 | 12/15 | | |
NCT01719601: A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain |
|
|
| Withdrawn | N/A | 0 | RoW | No intervention, Nucynta IR | Janssen Pharmaceutica | Moderate to Severe Acute Non-Cancer Pain | 11/16 | 11/16 | | |
NCT03351517: Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty |
|
|
| Completed | N/A | 90 | RoW | Tapentadol 100 MG, Placebo Oral Tablet | All India Institute of Medical Sciences, Bhubaneswar | Analgesia | 08/18 | 09/18 | | |
